SINGLETON J MATTHEW 4
4 · Viking Therapeutics, Inc. · Filed Aug 19, 2024
Insider Transaction Report
Form 4
SINGLETON J MATTHEW
Director
Transactions
- Sale
Common Stock, par value $0.00001 per share
2024-08-19$60.01/sh−2,500$150,035→ 23,000 total - Sale
Common Stock, par value $0.00001 per share
2024-08-19$61.86/sh−4,509$278,931→ 15,444 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-08-19$3.33/sh+16,000$53,280→ 25,500 total - Sale
Common Stock, par value $0.00001 per share
2024-08-19$61.13/sh−3,047$186,248→ 19,953 total - Sale
Common Stock, par value $0.00001 per share
2024-08-19$63.15/sh−2,055$129,775→ 13,389 total - Sale
Common Stock, par value $0.00001 per share
2024-08-19$64.10/sh−2,388$153,080→ 11,001 total - Sale
Common Stock, par value $0.00001 per share
2024-08-19$64.88/sh−1,501$97,385→ 9,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-19−16,000→ 0 totalExercise: $3.33From: 2017-01-04Exp: 2026-01-04→ Common Stock (16,000 underlying)
Footnotes (7)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.3605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5411 to $61.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5874 to $62.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.635 to $63.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.64 to $64.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.79 to $64.9056, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.